Topic:

Blockbusters

Latest Headlines

Latest Headlines

It's megablockbuster halfsies for Sanofi, Amgen in next new cholesterol market

When is cholesterol fighting a game of six of one, half dozen of the other? Could be when the contest is between Amgen and its PCSK9 inhibitor evolocumab, and Sanofi and Regeneron's rival alirocumab. Despite some dramatic new data from the latter team--and a first-up filing with the FDA by Amgen--analysts figure on a dead heat once the drugs hit the market.

Arkansas stiff-arms CF patients seeking Vertex's $300K drug Kalydeco: WSJ

The drug-pricing battle continues, but this time, Gilead Sciences' Sovaldi isn't at the center.  That dubious honor goes to Vertex Pharmaceuticals' cystic fibrosis treatment Kalydeco. According to a lawsuit filed by three CF patients, Arkansas Medicaid officials are locking them out of Kalydeco treatment.

J&J, GSK meds join Sovaldi, Tecfidera in blockbuster-to-be crowd

New drug approvals may have dropped from 2012's high of 43 to 35 last year. But that doesn't mean 2013's crop lacks superstars.

Second-line use, crowded market won't keep Takeda's Entyvio from blockbuster run

Takeda is finally over the hump with its inflammatory bowel disease drug Entyvio after safety questions threatened its approval. And while the drug will take a backseat to some of the market's heavyweights, some analysts say that won't stop it from hitting the blockbuster mark itself.

Novartis orphan drug Jakavi nabs 'blockbuster' forecasts on new data

Novartis may have another cancer blockbuster on its hands. New Phase III data on Jakavi (ruxolitinib) has Wall Street analysts predicting that it will easily pass the $1 billion mark.

J&J, Pharmacyclics get CLL approval for Imbruvica

Johnson & Johnson and Pharmacyclics' new drug Imbruvica won the expanded approval it needed to go beyond a rare disease treatment and reach the blockbuster status it was conceived for. The FDA Wednesday gave Imbruvica accelerated approval for treating chronic lymphocytic leukemia in patients who have received at least one previous therapy.

Move over, Big Pharma. Valeant's CEO plans to elbow his way in

J. Michael Pearson is one ambitious man. The Valeant ($VRX) CEO wants to elbow his way to the top echelons of the drug business. If he has his way, Valeant will be one of the top 5 drugmakers in the world. By 2016.

Bayer bids $2.4B for Xofigo partner Algeta in drive for cancer growth

When Bayer CEO Marijn Dekkers stepped into the job in 2010, he had a trove of cash, and he promised to spend a big chunk on deals. A $23 billion chunk, in fact. Since then, the German conglomerate hasn't exactly been audacious in the M&A arena. Bayer has snapped up a healthcare company or three, but it's quick to back away if a price gets too rich.

Top 15 Drug Launch Superstars

Herewith we bring you our Top 15 Drug Launch Superstars. Some of them will be obvious to anyone who follows the pharma business. They certainly were obvious to us. But choosing the rest was a challenge--one we weren't exactly expecting, based on previous experience. Read the full report >>

Lundbeck recruiting 200-plus sales reps for Brintellix launch

Lundbeck is fired up and ready for its launch of the potential blockbuster antidepressant Brintellix. Though still awaiting regulatory approval, the Danish drugmaker is recruiting more than 200 sales reps to prepare for take-off, Bloomberg reports.